ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026
I'm PortAI, I can summarize articles.
ProMIS Neurosciences Inc. announced that interim Phase 1b trial results for PMN310 in Alzheimer's disease will be available in Q2 2026. The trial uses plasma pTau biomarkers, including pTau217, as early endpoints. The upcoming readout aims to provide early insights into PMN310's potential disease-modifying effects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments